Table 1.

Unique interactions from the top 50 scoring edges based on the smoothed mutational score, pooled across all patients

Gene 1	Gene 2	Prop. score	Top rank	References
STEAP1B	STEAP1	0.300938	1	[49–51, 57]
TAS1R2	TAS1R3	0.277285	2
SCGB3A2	MARCO	0.244833	3	[52, 53]
CYP2A7	CYP2A13	0.244117	4	[47, 48]
CNGB1	ABCA4	0.242088	6	[58, 59]
PLXND1	SEMA3E	0.229689	12	[60]
GSTA5	GSTA2	0.211860	14	[61]
UGT2B15	UGT2A3	0.210076	15	[62, 63]
CX3CR1	CX3CL1	0.206455	16	[64–66]
GFRA3	ARTN	0.204744	21	[67–70]
GRID2	GRID2IP	0.202544	33	[71]
PLXNC1	SEMA7A	0.199880	34	[60, 72]
HAS2	HAS3	0.199088	35	[73, 74]
OBP2B	OBP2A	0.197566	37	[75, 76]
CD180	LY86	0.195079	39	[77, 78]
ZNF221	ZNF225	0.193870	42	[79, 80]
PSPN	GFRA4	0.192038	45	[81, 82]
LIPE	FABP9	0.190075	47	[83, 84]
KCNC1	KCNC2	0.189430	48	[85, 86]

References refer to prior information about the involvement of these proteins in breast or other types of cancers. See Additional file 1: Table S2 for complete details and more information